Drug Development Is Global. How Can Programs Move Across Regions Without Losing Momentum?

Drug development rarely stays in one place. WuXi AppTec has built its global network around that principle, connecting research, development and manufacturing capabilities through an integrated operating model. By maintaining a common global quality system to ensure consistent standards across sites, offering flexibility and options as programs evolve and require new capabilities, and reducing the number of external interfaces customers need to manage, WuXi AppTec’s global network functions less like a collection of individual sites and more like a connected system—one that can adapt as a program advances while maintaining continuity in quality and execution.

How WuXi AppTec Ensures Quality Across Its Global Network?

WuXi AppTec ensures quality across its global network through what it calls “One Global Quality System”—a framework designed to align quality standards, procedures and training across all sites. Rather than allowing individual sites to develop largely independent approaches, the system establishes shared GMP practices and standardized procedures intended to create continuity as programs move between locations and development stages.

That quality system extends to the infrastructure. Global digital platforms are used to manage documentation and quality data across sites, replacing processes that historically relied more heavily on paper and locally maintained records. Beyond improving access to information, the approach is intended to give teams in different regions a common way to document, review and interpret quality-related activities.

The underlying principle of this global quality system is straightforward: quality cannot be something performed only when someone is watching. A recent unannounced FDA inspection at one of WuXi AppTec’s manufacturing sites offered a real-world test of that philosophy. Such inspections are designed in part to give regulators a view of normal operations without the benefit of advance preparation. When FDA investigators arrived, the site’s teams continued working under their established procedures rather than shifting into a special inspection mode. The inspection concluded with no observations.

That is ultimately what “One Global Quality System” is intended to provide. As drug-development programs move across functions, facilities and regions, the location may change. The expectations governing how the work is performed should not.

How WuXi AppTec Gives Programs More Options as Their Needs Change?

WuXi AppTec’s global network can provide an important advantage in the moments when a program’s requirements change as it advances, giving customers more options to adapt without disrupting the program’s momentum.

One recent program illustrates how those needs can evolve. A biotech company worked with WuXi AppTec across drug substance and drug product to support the launch of a new drug addressing an unmet clinical need in China. The company subsequently entered into a partnership with a European pharmaceutical company to support the drug’s global expansion.

That shift changed the requirements for the program. The existing manufacturing capacity and supply chain, originally established for the China market, needed to support a potentially accelerated global development plan and significantly greater demand. At the same time, a key raw material sourced from another vendor did not meet the global quality requirements of the new partner.

WuXi AppTec worked with both partners to address the two challenges in parallel. Larger manufacturing trains at its Changzhou and Taixing sites were brought into the program to expand capacity and support increased clinical and potential commercial demand. Upstream, the company leveraged its ISO-certified manufacturing capabilities to back-integrate the raw material and regulatory starting material (RSM) into its own supply chain, helping the program meet the new partner’s quality requirements.

Image source: 123RF

The same flexibility can become important when timelines drive the change. In another program, a client needed to start manufacturing a Phase 3 drug from its own facility to WuXi AppTec’s Couvet site as production requirements increased. The work required more than moving an established process between facilities. Teams assessed equipment compatibility, validated analytical methods, and secured raw and packaging materials, with multiple activities planned and executed in parallel. The transition was completed in time to support the client’s NDA submission, and the drug was subsequently approved for market launch.

The circumstances of the two programs were different, but the underlying challenge was similar: the needs of the program had changed. In both cases, the value of a global network came not simply from having additional sites, but from being able to mobilize different capabilities as the program evolved. For drug developers, that optionality can become important as a molecule advances.

How WuXi AppTec Improves Global Execution Without Adding Complexity?

WuXi AppTec’s integrated global network improves global execution by providing access to capabilities across regions while keeping more of the development and manufacturing process within a connected system.

One targeted protein degrader program illustrates the difference. Before coming to WuXi AppTec, the customer was working with five external vendors to manufacture a single molecule. One vendor supplied the regulatory starting material (RSM), another produced the crude API, a third manufactured the final API, a fourth handled the spray-dried dispersion, and a fifth produced the final drug product. Those vendors were located across different countries and continents.

Managing so many interfaces created challenges beyond the science itself. Materials had to move repeatedly between vendors and regions, accompanied by method transfers, shipping and customs clearance. Taken together, those handoffs could add an estimated six to 12 months to the development timeline.

WuXi AppTec’s integrated platform provided another approach. The regulatory starting material, API, spray-dried dispersion and drug product could all be supported within the same network and under a common global quality system. Bringing these activities together reduced the number of external interfaces and transfers the customer needed to manage while maintaining access to the specialized capabilities required at each stage. In this case, the integrated approach helped accelerate the program by approximately six to 12 months without substantially changing the overall development workflow.

The example highlights a broader challenge in global drug development: complexity comes from the number of connections required to move a program forward. Integration can simplify those connections by bringing capabilities, quality systems and supply-chain planning together within the same network.

WuXi AppTec has continued to expand that model geographically. From Changzhou and Taixing in China to Munich in Germany, Couvet in Switzerland, Delaware in the United States, and Singapore, the company has been expanding its global manufacturing footprint. The objective is not simply to add more sites, but to connect capabilities across regions so customers can access the technologies, capacity and geographic options their programs require without having to assemble and coordinate a fragmented network of providers themselves.

Closing: One Global Network, Built to Move with the Program

As drug development becomes increasingly global, the value of a global network lies not simply in how many sites it includes, but in how effectively those sites work together. Consistent quality standards can help programs move across regions with confidence; access to capabilities across the network can provide flexibility as development needs change; and an integrated model can reduce the complexity created by multiple handoffs and external providers.

For WuXi AppTec, the goal is to make its global footprint operate as one connected system—allowing capabilities, capacity and resources across regions to be mobilized as programs evolve. Ultimately, as a molecule moves from one stage or geography to another, the location may change, but the continuity supporting its development should remain.